Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc

€ 710.40 (+1.88%) Sep 23
On watch
P/E:
13.92
P/B:
3.69
Market Cap:
€ 77.26B ($ 74.86B)
Enterprise V:
€ 72.31B ($ 70.07B)
Volume:
-
Avg Vol (2M):
30.00
Also Trade In:
Volume:
-
Market Cap €:
77.26B
Market Cap $:
74.86B
PE Ratio:
13.92
Avg Vol (2-Month):
30.00
Enterprise Value €:
72.31B
Enterprise Value $:
70.07B
PB Ratio:
3.69
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Financials (Next Earnings Date:2022-11-04 Est.)

WBO:REGN's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 12,712.357
EPS (TTM) (€) 44.492
Beta -0.21
Volatility % 21.88
14-Day RSI 67.91
14-Day ATR (€) 13.328972
20-Day SMA (€) 660.1
12-1 Month Momentum % 9.74
52-Week Range (€) 467.05 - 739.1
Shares Outstanding (Mil) 109.01

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Regeneron Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Regeneron Pharmaceuticals Inc Analysis

Share your research